1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dolphin Entertainment reported first-quarter 2026 results for the three months ended March 31, 2026. Revenue rose 5.2% year over year to $12.8 million, but the operating loss, net loss and loss per share all grew from the prior-year quarter, and the company said it reiterated its 2026 expectations for revenue growth, free cash flow and Adjusted EBITDA margin expansion.
Revenue was $12.8 million, up from $12.2 million in Q1 2025.
Operating loss was $2.1 million, compared with $1.8 million a year earlier; net loss was $2.7 million, compared with $2.3 million.
Basic and diluted loss per share was $(0.22), versus $(0.21), on 12,327,974 weighted average shares.
Adjusted EBITDA loss narrowed 25% to approximately $467,000 from $625,000, a non-GAAP measure.
IPM reported first-quarter 2026 revenue of $6.35 million, up 15.2% from a year earlier, and its operating loss narrowed by 42.4%. Net results turned to a $660,214 loss from $808,530 of net income, because the prior-year period included an income tax benefit of about $2.1 million that did not recur.
Total revenue was $6,354,751 versus $5,518,038 for Q1 2025, up 15.2%; procurement revenue rose 78.4% and core managed IT revenue rose 19%.
Loss from operations was $768,182 versus $1,333,927 a year earlier.
Net loss was $660,214, or $(0.05) per share, versus net income of $808,530, or $0.06 per share, in Q1 2025.
Net cash used in operating activities was $195,712, and cash and cash equivalents totaled $8.1 million at March 31, 2026, including $1.0 million of restricted cash.
PepGen reported a first quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $30.2 million, or $(0.92) per share, a year earlier, as research and development expenses fell to $13.0 million from $25.4 million. The company also disclosed that the FDA placed a partial clinical hold on its FREEDOM2 study of PGN-EDODM1, which PepGen says relates to previously submitted preclinical studies and has not affected the ongoing trial's timing, and that cash and marketable securities were $132.3 million as of March 31, 2026.
Q1 2026 net loss was $17.8 million, or $(0.26) per share, versus $30.2 million, or $(0.92) per share, in Q1 2025.
Research and development expenses were $13.0 million, compared with $25.4 million a year earlier; general and administrative expenses were $5.9 million in both periods.
The FDA placed a partial clinical hold on the FREEDOM2 study, tied to questions about previously submitted preclinical pharmacology and toxicology studies.
Cash, cash equivalents and marketable securities were $132.3 million at March 31, 2026, down from $148.5 million at December 31, 2025, and PepGen expects this to fund operations into the second half of 2027.
Lineage Cell Therapeutics reported first quarter 2026 results, with total revenues of $1.7 million, up from $1.5 million a year earlier. The net loss attributable to Lineage widened to $4.8 million, or $0.02 per share basic and $0.03 diluted, from $4.1 million, or $0.02 per share, in the prior-year quarter. The company said its $53.4 million in cash, cash equivalents and marketable securities is expected to support planned operations into Q2 2028.
Total revenues were $1.7 million for the quarter ended March 31, 2026, up $0.2 million, driven mainly by collaboration revenue under the new research collaboration agreement with William Demant Invest A/S (WDI).
Loss from operations was $7.6 million, compared with $6.5 million a year earlier, as total operating expenses rose to $9.3 million from $8.0 million.
Other income of $2.8 million, including a $2.3 million change in fair value of warrant liability, partly offset the operating loss.
Cash, cash equivalents and marketable securities totaled $53.4 million as of March 31, 2026.
Nextpower reported fiscal fourth-quarter 2026 revenue of $881 million and GAAP diluted EPS of $0.97, both below the year-earlier quarter, while full-year fiscal 2026 revenue rose to $3.56 billion and GAAP diluted EPS reached $3.84. The company raised its fiscal 2027 revenue outlook to $3.8 billion to $4.1 billion from $3.6 billion to $3.8 billion, and it also announced a planned acquisition of power conversion product lines subject to Spanish government approval.
Q4 FY26 revenue $881 million vs. $924 million in Q4 FY25; GAAP diluted EPS $0.97 vs. $1.05
Full-year FY26 revenue $3.56 billion; GAAP diluted EPS $3.84 vs. $3.47 in FY25
FY27 outlook: revenue $3.8 billion to $4.1 billion; Adjusted EBITDA $825 million to $900 million
Robert Vinje appointed Chief Operating Officer effective June 15, 2026; Marco Miller moves to Chief Project Development Officer
Evolv Technology reported first-quarter 2026 revenue of $46.3 million, up 45% from a year earlier, and ending annual recurring revenue of $127.3 million, up 20%. The company raised its 2026 total revenue outlook to $175 million to $180 million, but its net loss widened to $5.0 million from $1.7 million, which shareholders should weigh against the higher sales and guidance.
Q1 2026 revenue was $46.3 million, up 45% from $32.0 million in Q1 2025.
Net loss was $5.0 million, or $(0.03) per share, versus $1.7 million, or $(0.01) per share, in Q1 2025.
2026 total revenue outlook raised to $175 million to $180 million from $172 million to $178 million issued March 10, 2026.
Cash, cash equivalents and marketable securities were $61.1 million as of March 31, 2026.
Beachbody reported first-quarter 2026 revenue of $54.3 million, down from $72.4 million a year earlier, while net income was $2.3 million compared with a net loss of $5.7 million. The company also gave second-quarter 2026 revenue guidance of $46 million to $51 million and adjusted EBITDA guidance of $3 million to $6 million, so shareholders face shrinking sales alongside improved profitability.
Total revenue was $54.3 million, down 25.0% from $72.4 million; digital subscriptions totaled 0.81 million, down 20.6% from 1.02 million.
Operating income was $3.1 million, compared with an operating loss of $3.7 million a year earlier; net income was $2.3 million versus a net loss of $5.7 million.
Adjusted EBITDA was $8.0 million, up from $3.7 million, while free cash flow was negative $1.7 million compared with positive $1.6 million.
Second-quarter 2026 outlook calls for revenue of $46 million to $51 million and adjusted EBITDA of $3 million to $6 million.
TriSalus Life Sciences reported first quarter 2026 revenue of $8.9 million, down 2.9% from a year earlier, and revised its 2026 revenue guidance to $54 million to $57 million. Net income was $1.5 million, or $0.03 per share, but that result reflected $11.3 million of non-cash derivative gains, while the operating loss widened, so shareholders face a mixed picture.
Q1 2026 revenue was $8.9 million, down 2.9% from $9.2 million in Q1 2025, which the company attributed mainly to its commercial expansion.
Operating loss widened to $8.4 million from $7.3 million, and adjusted EBITDA loss widened to $5.8 million from $5.5 million.
Net income attributable to common stockholders was $1.5 million, or $0.03 per share, versus a net loss of $11.1 million, or $(0.39) per share, a year earlier; the company cited $11.3 million of non-cash fair value gains on derivatives.
2026 revenue guidance was revised to $54 million to $57 million, citing lower Q1 revenue and delayed FDA clearance timing for TriNav Advance; cash totaled $56.6 million on March 31, 2026, after a $46.0 million gross equity raise.
ACCESS Newswire reported first-quarter 2026 results for the three months ended March 31, 2026. Revenue fell 3% year over year to $5.3 million, while the net loss from continuing operations narrowed to $0.6 million, or $0.16 per diluted share, from $0.8 million, or $0.20 per share, a year earlier. Revenue and profit moved in opposite directions, and the filing gives no financial guidance.
Revenue was $5.3 million, down 3% from $5.5 million in Q1 2025 and down 8% from $5.8 million in Q4 2025.
Net loss from continuing operations was $611,000, or $0.16 per diluted share, compared with $765,000, or $0.20 per share, in Q1 2025.
Adjusted EBITDA was $564,000 in both Q1 2026 and Q1 2025; gross margin fell to 74% from 78%.
Subscription customers reached 1,119, and average ARR per customer rose to $12,803 from $11,139 a year earlier.
Under Armour reported fourth-quarter and full-year fiscal 2026 results on May 12, 2026. Revenue fell 1% to $1.2 billion in the quarter and 4% to $5.0 billion for the year, and the company posted a full-year net loss of $496 million. It also raised the total cost of its fiscal 2025 restructuring plan to approximately $305 million and gave initial fiscal 2027 guidance that includes operating income of $96 million to $116 million.
Q4 fiscal 2026 revenue fell 1% to $1.2 billion; net loss was $43 million, or $0.10 per share, versus a $67 million loss ($0.16 per share) a year earlier.
Full-year net loss was $496 million ($1.16 per share), including a $247 million valuation allowance on U.S. federal deferred tax assets.
Total fiscal 2025 restructuring plan costs were raised to approximately $305 million from the previous $255 million, with completion expected by December 31, 2026.
Fiscal 2027 outlook: operating income of $96 million to $116 million and GAAP diluted loss per share of breakeven to $0.04.
Ralliant reported first-quarter 2026 revenue of $535 million, up 11% from a year earlier, and raised its full-year 2026 outlook. GAAP net earnings fell to $44 million, or $0.39 per diluted share, from $63.9 million, or $0.57, a year earlier, so shareholders see higher sales alongside lower reported profit. The company also raised its share repurchase authorization to $500 million.
Revenue of $535 million, up 11% year over year and up 9% organically; net earnings of $44 million, or $0.39 per diluted share, versus $0.57 a year earlier
Full-year 2026 guidance: revenue of $2.185 to $2.245 billion and adjusted EPS of $2.53 to $2.69
Second-quarter 2026 guidance: revenue of $540 to $556 million and adjusted EPS of $0.58 to $0.64
Share repurchase authorization raised to $500 million on May 8, 2026, including a planned $100 million accelerated share repurchase in the second quarter
SOLV Energy reported first-quarter 2026 revenue of $677 million, up 66% from a year earlier, and a net loss of $27 million, which included a one-time, non-cash expense of $52 million tied to modifying legacy equity awards from its IPO reorganization. The company raised its full-year 2026 Adjusted EBITDA guidance to $435 million to $455 million. For shareholders, operating growth was strong, but the reported loss widened and the company's chief strategy officer stepped down from that role.
Revenue was $677 million versus $408 million a year earlier; Adjusted EBITDA was $93 million, up 174% from $34 million.
Net loss was $27 million, including a one-time, non-cash expense of $52 million from modifying legacy equity awards; basic and diluted loss per share was $0.20 for February 12 to March 31, 2026.
Full-year 2026 guidance: revenue of $3.720 billion to $3.820 billion and Adjusted EBITDA of $435 million to $455 million.
Erik Johnson resigned as Chief Strategy Officer effective May 11, 2026, and will remain an employee through the end of 2026.
Janus International reported first-quarter 2026 results for the quarter ended April 4, 2026. Revenue rose 5.8% to $222.7 million, but net income fell to $0.2 million from $10.8 million a year earlier, and adjusted EBITDA fell 14.1% to $33.0 million. The company reaffirmed its full-year 2026 guidance, which calls for total revenue of $940 million to $980 million and adjusted EBITDA of $165 million to $185 million.
Revenue was $222.7 million, up 5.8% from $210.5 million; New Construction revenue rose 10.9%, and the Kiwi II Construction acquisition contributed $18.1 million.
Net income was $0.2 million, or $0.00 per diluted share, versus $10.8 million, or $0.08 per diluted share, a year earlier; adjusted diluted EPS was $0.01 versus $0.13.
Full-year 2026 guidance was reaffirmed: total revenue of $940 million to $980 million and adjusted EBITDA of $165 million to $185 million.
During the quarter the company repurchased about 2.9 million shares for $15.7 million, and free cash flow was $33.4 million.
Qnity reported first-quarter 2026 net sales of $1.3 billion, up 18% from a year earlier, and raised its full-year 2026 guidance across all metrics. GAAP net income fell 19% to $162 million and GAAP diluted EPS fell 22% to $0.72, while adjusted EPS rose 33% to $1.08, a non-GAAP measure. Shareholders get higher sales and a raised outlook, but the GAAP profit decline is the key counterpoint.
Q1 2026 net sales $1,315 million, up 18% year over year; organic sales up 17%
GAAP net income $162 million, down 19%; GAAP diluted EPS $0.72, down 22%
Adjusted EPS $1.08, up 33%; adjusted operating EBITDA $411 million, up 22%
Full-year 2026 guidance: net sales $5.225 billion to $5.375 billion; adjusted EPS $3.80 to $4.14
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.